NEW YORK (360Dx) – Akers Biosciences today announced that it has reached a settlement agreement with Pulse Health, which had filed a lawsuit against it in September alleging a breach of contract under a settlement agreement entered into by the two firms in April 2011.

The firm today also announced a leadership change, an update to its business strategy, and the resignation of its nominated adviser on the London Stock Exchange's AIM market that could lead to Akers Bio's suspension from trading.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.